Navigation Links
NuVasive Prices $200 Million Convertible Senior Notes Due 2013
Date:3/4/2008

SAN DIEGO, March 4 /PRNewswire-FirstCall/ -- NuVasive, Inc. (Nasdaq: NUVA), a medical device company focused on developing products for minimally disruptive surgical treatments for the spine, announced the pricing of $200 million principal amount of 2.25% Convertible Senior Notes due 2013 through an offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. NuVasive has also granted the initial purchasers an option to purchase up to $30 million of additional notes solely to cover over-allotments. The offering is scheduled to close on March 7, 2008, subject to satisfaction of customary closing conditions.

The notes will pay interest semiannually at a rate of 2.25% per annum. The notes will be convertible into shares of NuVasive common stock at a conversion rate of 22.3515 shares of common stock per $1,000 principal amount of notes, which is equal to a conversion price of approximately $44.74 per share.

NuVasive estimates that the net proceeds from the offering will be approximately $193.4 million after deducting the initial purchasers' discounts and commissions and estimated offering expenses, assuming no exercise of the initial purchasers' over-allotment option.

NuVasive intends to use the net proceeds from the offering for general corporate purposes, including potential strategic acquisitions. NuVasive has entered into convertible note hedge transactions with the initial purchasers or their affiliates (the "counterparties") and intends to use a portion of the net proceeds from this offering to pay for the cost of the convertible note hedge transactions. The convertible note hedge transactions are intended to reduce dilution experienced by the company's stockholders upon potential future conversion of the notes. The company has also entered into separate warrant transactions with the counterparties, which would result in additional proceeds to the company, and would partially offset the
'/>"/>

SOURCE NuVasive, Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related medicine news :

1. NuVasive to Present at ThinkEquity Partners 5th Annual Growth Conference
2. NuVasive Announces Web Cast and Conference Call of Third Quarter 2007 Results
3. NuVasive Licenses Its Insert and Rotate Technology
4. NuVasive Cancels 10/24/07 Investor Reception Due to Concerns Over Southern California Fires
5. NuVasive to Present at BIOCOM Investor Conference 2007
6. NuVasive Announces Preliminary Unaudited Full Year 2007 Financial Results
7. NuVasive to Offer $200 Million Convertible Senior Notes Due 2013
8. Lincare Holdings Inc. Prices $500 Million Convertible Senior Debentures Offering
9. American Association for Homecare Disputes Validity of Internet Power Wheelchair Prices as Basis for Reimbursement of Services in Medicare
10. Mylan Prices Offerings of Common Stock and Mandatory Convertible Preferred Stock
11. Health care opinion leaders support public reporting of health care quality, prices
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/8/2009)..., ALEXANDRIA, Va., Jan. 8 /PRNewswire-USNewswire/ ... Organization along with several national leadersh...rding the principles of hospice care and protectio...ns standing together in sharing this unified messa...tion of Hospice and Palliative Medicine, Hospice a...
(Date:1/8/2009)..., California Assembly Member Tom Torlakson Introdu...swire-USNewswire/ -- Today, Lung Cancer Alliance...ember Tom Torlakson (D-11th District) for his cont...ing funding for lung cancer research. For the thi...ung cancer research is being considered in the Cal...
(Date:1/8/2009)...view says it lowered bad cholesterol more effectiv...lthDay News) -- After nearly a year of review, U.S...ed the continued use of the controversial choleste...Drug Administration said there was no significant ...ients taking Vytorin and patients taking the drug ...
(Date:1/8/2009)..., First Announced Acquisition in 2009 Continues Gr... IPC The Hospitalist Comp...spitalist physician group practice company, announ...ctice of Midwest Acute Care Consultants, Inc. (MAC...nts continued expansion in the St. Louis market, w...
Breaking Medicine News(10 mins):Health News:National End-of-Life Organizations Release Consensus Statement on Hospice, the Medicare Hospice Benefit, and Key Issues for the Future 2Health News:National End-of-Life Organizations Release Consensus Statement on Hospice, the Medicare Hospice Benefit, and Key Issues for the Future 3Health News:National End-of-Life Organizations Release Consensus Statement on Hospice, the Medicare Hospice Benefit, and Key Issues for the Future 4Health News:National End-of-Life Organizations Release Consensus Statement on Hospice, the Medicare Hospice Benefit, and Key Issues for the Future 5Health News:National End-of-Life Organizations Release Consensus Statement on Hospice, the Medicare Hospice Benefit, and Key Issues for the Future 6Health News:National End-of-Life Organizations Release Consensus Statement on Hospice, the Medicare Hospice Benefit, and Key Issues for the Future 7Health News:Lung Cancer Alliance Applauds New Legislation Funding Lung Cancer Research 2Health News:FDA Backs Cholesterol Drug Vytorin 2Health News:IPC The Hospitalist Company Acquires Missouri Practice Group 2
...ational TB Control Programme (RNTCP) aims at widen...uality treatment and diagnostic services to all tu...0 % of HIV-positive people are more prone to contr...amily Welfare Minister Anbumani Ramadoss plan to t...
...nducted by Steven M. Kurtz, of Exponent Inc., a Ph...ting firm//, there is an increase in demand for ar...artificial joints needed to replace damaged knees ...e study showed that the demand for artificial hips...
...ts had captured the market and minds of various pe...iny. // A number of detox products are to be inve... report by the BBC which drew its attention to som...he Medical Health Care Products Regulatory Agency ...
...ar, Nitish Kumar assured that the Bihar Government...ing spread of AIDS/HIV in the state //, addressing...ma foundation, Samyak and the National Aids Contro...oncern over the explosive prevalence of HIV/AIDS i...
Other Medicine News:Health News:India to Implement National Action Plan against TB-HIV 2
(Date:1/8/2009)...o, Jan. 8 IntelligentMDx a develope...ays, today announced that verification studies of ... complete. , , Under the verification protocol...d reproducibility and robustness of the BK Viral Q... agreed with internally generated analytical perfo...
(Date:1/7/2009)...re-FirstCall/ -- Eli Lilly and Company,(NYSE: L...esponse letter from,the U.S. Food and Drug Admini...on (LAI) for acute and maintenance treatment of sc...k with the agency on the new drug,application (ND...al clinical trials for the continued,review of th...
(Date:1/7/2009)...rease , , WHITE PLAINS, N.Y., Jan. 7 /PRNewswir... that the decades-long rise in the United States p...than ever at increased risk of death and disabilit...43,000 babies were born too soon in 2006, accordin...ich today released "Births: Final data for 2006," ...
(Date:1/7/2009)...opment Based On Osteotech,s Proprietary Human Coll...on; FDA Filing Anticipated in Third Quarter 2009 ...ll/ -- Osteotech, Inc. (Nasdaq: OSTE ), a lead...regenerative healing, announced today that it has ...h(TM) BioRegeneration Matrix. The first five patie...
Breaking Medicine Technology:Verification Studies of IntelligentMDx's Proprietary Molecular Diagnostic Assay Process Have Been Completed 2Verification Studies of IntelligentMDx's Proprietary Molecular Diagnostic Assay Process Have Been Completed 3FDA Issues a Complete Response Letter for Lilly's Olanzapine LAI for Treatment of Schizophrenia in Adults 2FDA Issues a Complete Response Letter for Lilly's Olanzapine LAI for Treatment of Schizophrenia in Adults 3FDA Issues a Complete Response Letter for Lilly's Olanzapine LAI for Treatment of Schizophrenia in Adults 4FDA Issues a Complete Response Letter for Lilly's Olanzapine LAI for Treatment of Schizophrenia in Adults 5FDA Issues a Complete Response Letter for Lilly's Olanzapine LAI for Treatment of Schizophrenia in Adults 6Preterm Births Rise 36 Percent Since Early 1980s 2Osteotech Initiates Pivotal Clinical Trial for DuraTech(TM) BioRegeneration Matrix 2Osteotech Initiates Pivotal Clinical Trial for DuraTech(TM) BioRegeneration Matrix 3MINRAD International Inc Announces FDA Approval of Petrem 28TM 29 Sevoflurane 21372 1MINRAD International Inc Announces FDA Approval of Petrem 28TM 29 Sevoflurane 21372 2Congressional Leaders and Mens Health Network Emphasize the Importance of Health During the 15th Annual National Mens Health Week 21370 1Congressional Leaders and Mens Health Network Emphasize the Importance of Health During the 15th Annual National Mens Health Week 21370 2Consumer Reports 3A Patients Overdose on Debt As Lenders Doctors and Hospitals Push Risky Credit to Pay for Medical Care 21368 1Consumer Reports 3A Patients Overdose on Debt As Lenders Doctors and Hospitals Push Risky Credit to Pay for Medical Care 21368 2Consumer Reports 3A Patients Overdose on Debt As Lenders Doctors and Hospitals Push Risky Credit to Pay for Medical Care 21368 3Consumer Reports 3A Patients Overdose on Debt As Lenders Doctors and Hospitals Push Risky Credit to Pay for Medical Care 21368 4Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ 004 28Staccato 28R 29 Loxapine 29 for Acute Agitation 2375 1Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ 004 28Staccato 28R 29 Loxapine 29 for Acute Agitation 2375 2Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ 004 28Staccato 28R 29 Loxapine 29 for Acute Agitation 2375 3Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ 004 28Staccato 28R 29 Loxapine 29 for Acute Agitation 2375 4Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ 004 28Staccato 28R 29 Loxapine 29 for Acute Agitation 2375 5Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ 004 28Staccato 28R 29 Loxapine 29 for Acute Agitation 2375 6Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ 004 28Staccato 28R 29 Loxapine 29 for Acute Agitation 2375 7
...uly 11, 2007 /PRNewswire-FirstCall/ -- On Wednesda...astern/10:30 p.m.,Central European Time members of...ill host a conference call to discuss today,s,anno...I RAPID trial,comparing CHOP-R to CPOP-R, in which...dard CHOP-R, in first-line treatment of patients,w...
...ion ,Automation continues to gain importance in...ing test consolidation, rising demands from clinic...ing shortage of licensed medical technologists. Ul...lity automation solutions are better equipped to m...t of overall laboratory automation (e.g. sample pr...
Other Medicine Technology:Cell Therapeutics, Inc. Management to Discuss Today's Announcement,of Interim Pixantrone Study Results 2Optimizing Quality Control Data Management 2Optimizing Quality Control Data Management 3Optimizing Quality Control Data Management 4Optimizing Quality Control Data Management 5
2.5 mm cups angled 50 degrees, 10 mm from angle to tip. Serrated handle with polished finish.
Two rows of teeth on jaws provide a firm purchase on the nucleus fragment for removal. Flat handle with dull finish.
Puntenney curved forceps, curved, smooth 10 mm platforms.
Curved, very delicate, smooth jaws with platforms., ,Straight, very delicate, smooth jaws with platforms.
Medicine Products: